Is Atrys Health, S.A. a good investment? Atrys Health, S.A. (ATRY.MC) is currently trading at 2.59 EUR. Market analysts have a consensus price target of 4.83 EUR. This suggests a potential upside from current levels.
Earnings Schedule: Atrys Health, S.A. is expected to release its next earnings report on March 3, 2027. The market consensus estimate for Forward EPS is 0.15.
No, it does not currently pay a dividend.
Atrys Health, S.A. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
The next earnings date is projected to be March 3, 2027. The company currently has a trailing EPS of -0.63.
Atrys Health, S.A., together with its subsidiaries, provides diagnostic services and medical treatments in Spain, Portugal, and Latin America. It operates through three segments: Diagnosis, Oncology, and Preventive Medicine. The company offers integrated diagnostics services comprising structural and molecular pathology, genetics, and nuclear medicine diagnosis; telediagnosis activities in the fields of radiology and cardiology; oncology treatment services, such as chemotherapy, immunotherapy, radiotherapy, and brachytherapy; second opinion and genetic counselling; and diagnostic reports and genetic tests. It also provides telemedicine services, such as teleradiology, telecardiology, teleoncology, teledermatology, teleophthalmology, and teleconsultations; prevention plans for companies, which includes training plans on occupational risk prevention; Smart Data, a technological database for healthcare; and research and development services. The company was formerly known as Althia Health, S.L. and changed its name to Atrys Health, S.A. in May 2016. Atrys Health, S.A. was incorporated in 2007 and is headquartered in Madrid, Spain.
| Split Date | Split Ratio to 1 |
|---|---|
| Jan. 2, 2018 | 1.075 |
| Oct. 30, 2019 | 1.014 |
| Sept. 17, 2020 | 1:2 |
Community Discussion